CoraLite® Plus 647-conjugated Ki-67 Recombinant antibody

• 

  IF Staining of HeLa using CL647-84192-4

  Immunofluorescent analysis of (4% PFA) fixed HeLa cells using CoraLite® Plus 647 Ki-67 antibody (CL647-84192-4, Clone: 241499E7 ) at dilution of 1:200, CL488-phalloidin (green).

Ki-67 Uni-rAb^TM Recombinant Antibody for IF/ICC

Cat No. CL647-84192-4

Clone No.241499E7

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

Synonyms

KI67, MKI67, 241499E7, Antigen identified by monoclonal antibody Ki-67, Antigen KI-67

---

Tested Applications

• Positive IF/ICC detected in: HeLa cells

Recommended dilution

• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL647-84192-4 targets Ki-67 in applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: Peptide
• Full Name: antigen identified by monoclonal antibody Ki-67
• Calculated Molecular Weight: 359 kDa
• GenBank Accession Number: NM_002417
• Gene Symbol: KI67
• Gene ID (NCBI): 4288
• Conjugate: CoraLite® Plus 647 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 654 nm / 674 nm
• Form: Liquid
• Purification Method: Protein A purification
• UNIPROT ID: P46013
• Storage Buffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

The Ki-67 protein (also known as MKI67) is a cellular marker for proliferation. Ki67 is present during all active phases of the cell cycle (G1, S, G2 and M), but is absent in resting cells (G0). Cellular content of Ki-67 protein markedly increases during cell progression through S phase of the cell cycle. Therefore, the nuclear expression of Ki67 can be evaluated to assess tumor proliferation by immunohistochemistry. It has been demonstrated to be of prognostic value in breast cancer. In head and neck cancer, several studies have reported an association between high proliferative activity and poorer prognosis.